Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma

NCT05472948 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Adenocarcinoma of Small Intestine
Appendix Carcinoma
Metastatic

Interventions

DRUG: Surufatinib
DRUG: Sintilimab
DRUG: Capecitabine

Sponsor

Sun Yat-sen University